AZN

PQNT · Weight decrease · 2d

The consecutive daily weight decreases for AstraZeneca, moving from 2.09% to 1.73% between July 5th and July 16th, 2026, reflect a measured reduction in exposure by Pictet Asset Management's PQNT. This graduated trimming, rather than an abrupt sell-off, aligns with the fund’s periodic rebalancing schedule and its integration of AI signals with factor exposures. Given AZN's significant +136.7% 1-year return, juxtaposed against its recent -13.3% 90-day return and current price at 80% of its 52-week high, the AI-driven methodology likely flagged a shift in momentum or valuation. The fund's strategy, targeting developed-international stocks ex-US, thus appears to be incrementally adjusting its position in the health care company based on these converging quantitative signals.

weight 1.800% → 1.730% (-0.070 pp)·stock down 4.5% in the 30 days before

Jul 16·entry $169.29·now $164.52

PQNT · Weight decrease · 3d

AstraZeneca's weighting in PQNT exhibited a clear pattern of consecutive decreases, shifting from a stable 2.09% to 1.80% across several trading days in July, indicating a deliberate, stepped reduction of exposure. This sequential adjustment is consistent with Pictet's AI-managed strategy, which integrates factor exposures like momentum and valuation, likely reacting to AZN's recent 30-day return of -7.4% and 90-day return of -14.9%. Despite a prior one-year return of +145.7%, the AI’s re-evaluation of AZN at its current $171.61, still at 82% of its 52-week high, suggests a recalibration based on evolving signals. The newer fund's periodic rebalancing schedule, rather than daily adjustments, allowed for this methodical reduction of a healthcare position within its broad international developed-market portfolio.

weight 2.090% → 1.800% (-0.290 pp)·stock down 6.4% in the 30 days before

Jul 12·entry $169.47·now $164.52

PQNT · Weight decrease · 2d

The detected pattern in PQNT's allocation to AstraZeneca reveals a subtle, stepped decrease over two consecutive trading days, specifically reducing weight from 2.09% to 2.01% on July 9th and 10th. This graduated trimming aligns with Pictet Asset Management's AI-driven strategy, which integrates momentum and sentiment signals, as AstraZeneca's price data shows significant recent deterioration. While the health care stock posted a +145.7% 1-year return, its 30-day return of -7.4% and 90-day return of -14.9%, combined with its current price at 82% of its 52-week high, suggest a decline in short-term positive drivers. The AI overlay within this ex-US developed-market fund likely flagged these weakening short-term factors in AZN, prompting a measured, periodic rebalancing decision to reduce exposure rather than an immediate, drastic change.

weight 2.090% → 2.010% (-0.080 pp)·stock down 6.4% in the 30 days before

Jul 10·entry $171.61·now $164.52

PQNT · Weight decrease · 2d

Pictet Asset Management’s PQNT, which systematically applies AI signals combined with factor exposures across approximately 300 international developed-market stocks, adjusted its weight in AstraZeneca following recent shifts in the company's profile. The fund's consecutive weight decrease for AZN, moving from 2.07% to 2.03% between July 1st and 2nd, indicates its machine learning models likely re-evaluated momentum and valuation signals. Despite a +159.8% 1-year return, AZN's more recent -10.3% 90-day return at its current $183.86 price point could have triggered this periodic rebalancing decision, reflecting the AI's response to an evolving risk-reward assessment.

weight 2.070% → 2.030% (-0.040 pp)·stock up 10.0% in the 30 days before

Jul 2·entry $195.15·now $164.52

PQNT · Weight decrease · 2d

AstraZeneca’s 1-year return of +150.3% has positioned the stock at $182.28, 87% of its 52-week high, following a period of considerable price appreciation. Pictet Asset Management's PQNT, which combines AI signals with valuation and momentum factor exposures within its developed-international universe, registered consecutive weight decreases in AZN from 2.06% on June 8th to 2.01% on June 12th. This systematic reduction aligns with the fund’s AI overlay and factor model identifying a potential shift in momentum or an unfavorable valuation after such a significant climb. The stock’s -2.7% 30-day return and -1.1% 90-day return, preceding and occurring during this rebalancing period, suggest the AI perceived a cooling trend. This managed decrease in exposure reflects the newer fund’s strategy to optimize its circa 300 international developed-market stock holdings in response to changing market signals.

weight 2.060% → 2.010% (-0.050 pp)·stock down 4.8% in the 30 days before

Jun 12·entry $178.75·now $164.52

PQNT · Weight decrease · 2d

weight 2.010% → 1.960% (-0.050 pp)·stock up 0.3% in the 30 days before

Jun 4·entry $181.80·now $164.52

PQNT · Weight decrease · 3d

The AI ETF likely initiated the consecutive weight decrease for AZN after processing a range of data points indicating a deteriorating outlook or an increased risk profile for AstraZeneca. This could include negative news concerning drug trials, regulatory updates, competitive landscape shifts, or a general downturn in healthcare sector sentiment, leading the algorithm to reduce exposure and reallocate capital. For a retail investor, this pattern should serve as a practical alert to conduct immediate and thorough due diligence on AZN and the broader healthcare sector. It emphasizes the importance of actively monitoring investments and being prepared to adjust one's own position based on evolving information, rather than passively holding a stock.

weight 1.990% → 1.930% (-0.060 pp)·stock down 10.8% in the 30 days before

May 10·entry $181.86·now $164.52

PQNT · Weight decrease · 2d

The AI ETF's consecutive weight decrease in AstraZeneca suggests its algorithms have identified persistent negative signals, potentially related to fundamental shifts like drug pipeline setbacks, increased competition, or a re-evaluation of its valuation relative to market alternatives. For a retail investor, this action by a sophisticated AI system should serve as a prompt for immediate personal due diligence into AZN's recent news and sector trends, verifying if their own investment thesis remains valid despite the AI's decision to de-risk.

weight 1.990% → 1.950% (-0.040 pp)·stock down 10.8% in the 30 days before

May 8·entry $182.85·now $164.52

PQNT · Weight decrease · 2d

The AI ETF is likely de-weighting AZN due to its algorithms detecting weakening momentum, increasing short-term risk, or a programmatic shift away from the healthcare sector's current attractiveness. For retail investors, this consistent reduction suggests the AI sees diminishing relative value or increasing headwinds for AZN, warranting independent research into the company's recent performance or broader sector outlook.

weight 2.080% → 2.010% (-0.070 pp)·stock down 4.5% in the 30 days before

Apr 29·entry $185.20·now $164.52